The International Journal of Biopharmaceutical Manufacturing and Therapeutic Advances (IJBMTA) is committed to providing immediate and unrestricted access to the latest scientific advancements in the field. Our Current Issue features peer-reviewed articles highlighting innovative research, industrial developments, and therapeutic breakthroughs.
Featured Articles in the Latest Issue
- Volume 2 (Issue 1) JANUARY- JUNE 2026
Research Articles
Advanced Bioreactor Optimization for Monoclonal Antibody Production Using AI-Driven Control Systems
Vol.2(1); Pages:1-10. Published on March-2026
Abstract
The increasing demand for monoclonal antibodies has intensified the need for efficient and scalable biomanufacturing processes. This study explores the integration of artificial intelligence (AI)-driven control systems into bioreactor operations to enhance productivity and process stability. Using a fed-batch culture system, we implemented machine learning algorithms capable of real-time monitoring and adaptive parameter optimization, including pH, dissolved oxygen, and nutrient feed rates. Experimental validation demonstrated a 28% increase in antibody yield and a 15% reduction in process variability compared to conventional control methods. Furthermore, the AI model successfully predicted metabolic shifts, enabling preemptive adjustments that minimized cell stress and apoptosis. Data analysis confirmed improved glycosylation consistency, which is critical for therapeutic efficacy. The study highlights the transformative potential of AI in biopharmaceutical manufacturing, offering a scalable and cost-effective approach to meet global therapeutic demands. Future research should focus on regulatory integration and cross-platform adaptability of such intelligent systems.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Reconfiguring Lipid-Based Nanodelivery Systems to Improve mRNA Therapeutic Performance
Vol.2(1); Pages:11-20. Published on April-2026
Abstract
Messenger RNA (mRNA)-based therapeutics have emerged as a promising modality for treating a wide range of diseases. However, efficient delivery remains a major challenge due to instability and rapid degradation. This study investigates novel lipid nanoparticle (LNP) formulations designed to improve mRNA encapsulation efficiency, stability, and cellular uptake. Various ionizable lipids, cholesterol ratios, and PEGylated lipids were systematically evaluated using microfluidic mixing techniques. The optimized formulation achieved over 95% encapsulation efficiency and demonstrated enhanced transfection in human epithelial cell lines. Stability testing under physiological conditions indicated prolonged mRNA integrity for up to 72 hours. In vitro assays confirmed reduced cytotoxicity and improved protein expression levels compared to conventional LNP systems. Additionally, mechanistic studies revealed enhanced endosomal escape facilitated by optimized lipid composition. These findings provide critical insights into LNP design for next-generation mRNA therapeutics, with implications for vaccine development and gene therapy applications. Further in vivo validation is recommended to assess translational potential.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Continuous Manufacturing Approaches for Recombinant Protein Therapeutics: A Comparative Evaluation
Vol.2(1); Pages:21-29. Published on April-2026
Abstract
Continuous manufacturing has emerged as a transformative approach in the production of recombinant protein therapeutics, offering advantages in efficiency, scalability, and quality control. This study compares traditional batch processing with continuous biomanufacturing systems using a model recombinant protein. Key performance indicators, including yield, purity, production time, and operational cost, were systematically evaluated. Results indicate that continuous systems achieved a 35% reduction in production time and a 20% decrease in operational costs while maintaining comparable product purity and bioactivity. Process analytical technologies (PAT) enabled real-time monitoring, ensuring consistent product quality. The study also identified challenges related to system integration, equipment validation, and regulatory compliance. Despite these challenges, the findings support the adoption of continuous manufacturing as a viable alternative to batch processing. The integration of automation and digital monitoring further enhances process robustness, making it a promising strategy for future biopharmaceutical production frameworks.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Stability Assessment of Biosimilar Insulin Under Variable Storage Conditions
Vol.2(1); Pages:30-38. Published on April-2026
Abstract
The stability of biosimilar insulin products is critical to ensure therapeutic efficacy and patient safety, particularly in regions with inconsistent storage conditions. This study evaluates the physicochemical and biological stability of a commercially available biosimilar insulin subjected to varying temperature and humidity conditions over a 90-day period. Analytical techniques, including high-performance liquid chromatography (HPLC), circular dichroism spectroscopy, and bioassays, were employed to assess structural integrity and potency. Results demonstrated significant degradation at temperatures exceeding 30°C, with a marked decline in biological activity after prolonged exposure. Conversely, samples stored under recommended conditions maintained stability throughout the study duration. The study also identified aggregation as a primary degradation pathway, potentially impacting immunogenicity. These findings underscore the importance of stringent storage protocols and highlight the need for improved packaging solutions to enhance thermal stability. The research provides valuable insights for regulatory guidelines and distribution strategies in diverse climatic regions.
View Full PDF
Please LOGIN to View Full PDF or Read more.
CRISPR-Based Gene Editing in Biopharmaceutical Cell Lines for Enhanced Protein Yield
Vol.2(1); Pages:39-48. Published on May-2026
Abstract
Gene editing technologies, particularly CRISPR-Cas9, have revolutionized the development of high-yielding cell lines in biopharmaceutical manufacturing. This study investigates the targeted modification of Chinese Hamster Ovary (CHO) cells to enhance recombinant protein production. Specific gene knockouts and insertions were performed to optimize metabolic pathways and reduce byproduct formation. Edited cell lines exhibited a 40% increase in protein yield and improved growth kinetics compared to wild-type controls. Genomic stability and off-target effects were assessed using next-generation sequencing, confirming high specificity of the editing process. Additionally, transcriptomic analysis revealed upregulation of key biosynthetic pathways contributing to enhanced productivity. The study demonstrates the feasibility of CRISPR-based strategies in industrial bioprocessing and highlights their potential to reduce manufacturing costs. However, regulatory considerations and long-term stability of edited cell lines remain areas for further investigation. This work contributes to the advancement of precision engineering in therapeutic protein production.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
